Entries by blueoxygen

9 October 2012

LoneStar Heart Inc. today announced the completion of an up to $20 million milestone-based equity financing to support the clinical testing and regulatory clearance of its lead product, Algisyl-LVR, a single-use, self-gelling biopolymer implanted into the heart’s left ventricle during surgery for the treatment of advanced heart failure. Themes Investment Partners (“Themes”), a Hong Kong-based […]

2 October 2012

Press release – LoneStar Heart Inc. today announced the first patient was treated in the company’s international multi-center AUGMENT-HF clinical trial of Algisyl-LVR at IRCCS San Raffaele Pisana and at Umberto I Policlinico, both located in Rome, Italy. Click here to read the complete release.

29 May 2012

LAGUNA HILLS, Calif., May 29, 2012 —LoneStar Heart Inc., today announced the advancement of a new therapeutic strategy aimed at genetic reprogramming of cardiac fibroblasts into functioning heart muscle cells to treat damage following a heart attack and other forms of heart disease.

28 March 2012

Data from LoneStar Heart’s first-in-man study has recently been published in Cell Transplantation. Free full text for Lee et. al. “Polymer-based restoration of left ventricular mechanics” is available here.